PanTera
Mol, BE · 5 known investors
PanTera develops actinium-225, a therapeutic radioisotope used in precision cancer treatment through radiotheranostics, serving oncology patients and pharmaceutical companies globally. The company operates a production facility in Belgium producing high-purity actinium-225 as an active pharmaceutical ingredient for personalized nuclear medicine treatments.
BiotechDeep TechHealthtechMedical Devices
Founders & leadership
SV
Sven van den bergheCEO
CM
Christophe MaliceCBO
SB
Samy BertrandCTO
YS
Yves SterckxDirector of Finance & Administration
PV
Philippe VanwolleghemDirector Quality, Regulatory Affairs & HSE
Investors · 5
Competitors · 4
by search overlapShinefusion19 shared keywordsShineFusion develops fusion energy technology, pursuing a step-by-step commercialization approach that generates revenue from intermediate applications to fund progress toward clean fusion power.
TerraPower17 shared keywordsTerraPower develops advanced nuclear reactors and related technologies to generate carbon-free electricity and heat for industrial decarbonization, while also producing radioisotopes for medical cancer treatments. The company addresses climate change and energy security through innovative nuclear technology.
Phys17 shared keywordsPhys.org is a science news website that publishes daily articles on research and developments across physics, chemistry, biology, earth sciences, technology, and other scientific fields. It aggregates and reports on peer-reviewed studies and academic research for a general and scientifically interested audience.
Actinium Pharmaceuticals, Inc.15 shared keywordsActinium Pharmaceuticals develops targeted radiotherapies using Actinium-225, including CD33-targeting Actimab-A for relapsed/refractory AML and ATNM-400, a pan-tumor radiotherapy for metastatic castration-resistant prostate cancer, NSCLC and breast cancer. The company also develops targeted conditioning agents for gene and cell therapy and holds Actinium-225 manufacturing technology.
Companies competing with PanTera for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does PanTera do?
- PanTera develops actinium-225, a therapeutic radioisotope used in precision cancer treatment through radiotheranostics, serving oncology patients and pharmaceutical companies globally. The company operates a production facility in Belgium producing high-purity actinium-225 as an active pharmaceutical ingredient for personalized nuclear medicine treatments.
- Who are PanTera's investors?
- PanTera's investors include EQT Life Sciences, Korys, Kurma Partners, LSP (Life Sciences Partners), PMV.
- Where is PanTera headquartered?
- PanTera is headquartered in Mol, BE.